Drug intelligence / Profile preview

cisplatin + cyclophosphamide + epirubicin + interferon α2b

Development stage: Unknown
Lead developer: Michigan State University
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous, Intramuscular

Overview

A combination chemotherapy regimen consisting of cisplatin, cyclophosphamide, epirubicin, and interferon α2b. This regimen has been studied primarily for the treatment of advanced non-small cell lung cancer. The chemotherapeutic agents (cisplatin, cyclophosphamide, and epirubicin) target DNA replication and cell division through different mechanisms, while interferon α2b provides immunomodulatory effects.

Other names: CAP + interferon α2bCAP chemotherapy with r alpha IFN

Targets

IFNAR (Immune system modulation via type I interferon receptor)DNA

Beyond the preview

Go deeper on cisplatin + cyclophosphamide + epirubicin + interferon α2b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + cyclophosphamide + epirubicin + interferon α2b.

Explore the full profile